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Introduction
1. Creation of guidelines
This guideline was developed by psychiatrists who are in active
clinical practice and was elaborated during the Brazilian
Psychiatric Congress – 2003.
This guideline aims at providing guidance to psychiatrists and
other mental health professionals who treat patients with Opioid
Dependence Syndrome. It comments on the somatic and
psychosocial treatment that is used for such patients, and reviews
scientific evidences and their strength.
The terminology used in this guideline is consistent with the
ICD-10 Classification of Mental and Behavioral Disorders.1
The reader is encouraged to consult this guideline and the
accompanying references when specific treatment recommendations are
sought for. However, this text is not intended to stand by itself, as data are
subjected to change as scientific knowledge and technology advances.
2. Definitions of terms
1) Opioid Physical Dependence – demonstrated by the presence
of opioid withdrawal on cessation of/or a marked reduction in
opioid use, or on the acute administration of an opioid antagonist.
The signs and symptoms of opioid withdrawal have been well
characterized, and include features such as rhinorrhea,
gooseflesh, and mydriasis (Table 2).
2) Opioid Dependence Syndrome (Addiction) – characterized
by a clustering of signs and symptoms associated with pathologic
use of opioids; an alternative term that can be used for syndromic
opioid dependence is opioid addiction. One feature of this
syndrome of dependence can be physical dependence, although
Brazilian guideline for the treatment of patients
with opioids dependence syndrome
Diretrizes para o tratamento de pacientes com
síndrome de dependência de opióides no Brasil
Danilo Antonio Baltieri,a,b Eric C Strain,c João Carlos Dias,d Sandra Scivoletto,a André
Malbergier,a Sérgio Nicastri,e Cláudio Jerônimof and Arthur Guerra de Andradea,b
Study performed at the Chemical Dependence Department of the Psychiatric Brazilian Association (ABP)
aInterdisciplinary Group of Studies on Alcohol and Drugs of the Psychiatric Institute of the Clinical Hospi-
tal of the University of São Paulo
bMedical School of ABC, Brazil
cJohns Hopkins University, School of Medicine
dPsychiatric Brazilian Association (ABP), Chemical Dependence Department
eAlbert Einstein Hospital, São Paulo, Brazil
fFederal University of São Paulo (UNIFESP) – UNIAD, Brazil
Abstract
There is a relatively low prevalence of opioid use in Brazil, particularly involving the non-medical use of codeine and opiate-
containing syrups. However, opioid dependence syndrome shows a significant total impact on mortality and morbidity. Over the
past 20 years, scientific progress has changed our understanding of the nature of opioid addiction and its various possible
treatments. Addiction is a chronic illness treatable if the treatment is well-delivered and tailored to the needs of the particular
patient. There is indeed an array of treatments that can effectively reduce drug use, help manage drug cravings, prevent relapses
and restore people to productive social functioning. The treatment of drug addiction will be part of long-term, medical, psychological,
and social perspectives.
This guideline aims at providing guidance to psychiatrists and other mental health professionals who care for patients with Opioid
Dependence Syndrome. It comments on the somatic and psychosocial treatment that is used for such patients, and reviews
scientific evidences and their strength. Also, the essential historical, epidemiological and neurobiological aspects of Opioid
Dependence are reviewed.
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Resumo
Existe uma prevalência relativamente baixa do uso de ópioides no Brasil, em particular envolvendo o uso não médico da codeína e
de xaropes que contêm opióides. No entanto, a síndrome de dependência apresenta um significativo impacto total na mortalidade
e morbidade. Nos últimos 20 anos, o avanço científico tem modificado nosso entendimento sobre a natureza da adição aos opióides
e os variados tratamentos possíveis. A adição é uma doença crônica tratável se o tratamento for realizado e adaptado tendo em vista
as necessidades do paciente específico. Há, de um fato, um conjunto de tratamentos que podem efetivamente reduzir o uso da
droga, ajudar a gerenciar a fissura pela droga, prevenir recaídas e recuperar as pessoas para o funcionamento social produtivo. O
tratamento da dependência de drogas será parte de perspectivas de longo prazo do ponto de vista médico, psicológico e social.
Esta diretriz almeja fornecer um guia para os psiquiatras e outros profissionais de saúde que tratam de pacientes com Síndrome
de Dependência de Opióides. Ela tece comentários sobre o tratamento somático e psicossocial que é utilizado nesses pacientes
e revisa as evidências científicas e seu poder. Da mesma forma, os aspectos históricos, epidemiológicos e neurobiológicos da
dependência de opióides são revisados.
Descritores: Entorpecentes; Transtornos relacionados ao uso de opióides/terapia; Transtornos relacionados ao uso de substâncias/
terapia; Diretrizes para a prática clínica.
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Table 1 – Opioid classification
Natural Opioids Opium, morphine, codeine, tebaine
Semi-synthetic Opioids Heroine, oxycodone, hydrocodone, Oxymorphone
hidromorphone
Synthetic Opioids Methadone, meperidine, fentanyl, L-alfa-acetyl
metadol or Levometadil (LAAM), propoxyphene
Mixed Antagonists Buprenorphine, nalbuphine, pentazocine, nalbuphine
Antagonists Naltrexone, naloxone
the presence of physical dependence is not required for the
diagnosis of syndromic dependence. Criteria for syndromic
dependence, such as those found in the DSM-IV – American
Psychiatry Association - are widely used.
3) Tolerance – Tolerance develops when after repeated
administration, a given dose of a drug produces a decreased
effect, or conversely, when increasingly larger doses must be
administered to obtain the effects observed with the original dose.
4) Relapse – The recurrence on discontinuation of an effective medical
treatment of the original condition from which the patient suffered.
5) Withdrawal – The psychological and physiological reactions
to abrupt cessation or reduction of the drug dose.2
Epidemiology
1. Use of illicit opioids around the world
In 1994 the United States (U.S.) Office of National Drug Control
Policy (ONDCP) reported some key trends in heroin use: more
teenagers and young adults and more middle- and upper-middle-
class people were using purer heroin, and the proportion of people
seeking for treatment continued to increase. Around 2000 –
2001 the number of opium or heroin abusers was estimated at
almost 15 million (0.2% of the world population).3
The 1999 National Household Survey on Drug Abuse (NHSDA) reports
the use of illicit drugs by people aged 12 and over. Lifetime prevalence (at
least one use in a person’s lifetime) of heroin use for people aged 12 and
over was 1.4%. By age group, 0.4% were in the 12-17 range; 1.8%
were in the 18-25 range; and 1.4% were users aged 26 and over.4
In 2002 the main illegal opium producing countries were
Afghanistan (76%), Mianmar (18%), Laos (2%) and Colombia (1%).
In spite of scant data, prevalence rates for alcohol and illicit drug abuse
among doctors seem to be similar to those in the general population.5 As
regards prescription drugs, like benzodiazepines, amphetamines and
opioids, however, prevalence among doctors is apparently higher than in
the general population, due to easier access to theses drugs.6-7
2. Use of illicit opioids in Brazil
Surveys on drug use among students included students from of 1st and
2nd grade inpublic schools in 10 Brazilian capitals from all regions of the
country, and were carried out in 1987, 1989, 1994 and 1997. The
data presented in the IV survey suggest a relatively low prevalence of
opioid use in Brazil, particularly involving the non-medical use of codeine
and opiate-containing syrups. Lifetime use rates were 1% for syrups
(ranging from 0.6% in São Paulo to 1.5% in Salvador) and 0.7% for
opioids (ranging from 0.2% in Rio de Janeiro to 1.4% in Porto Alegre).
A statistically significant increase in lifetime use of opioids was noticed
only in Salvador. Only 12 students (in a sample of more than 15,000)
reported having already used injectable heroin: three in Porto Alegre, two
in Belo-Horizonte, Brasilia and Curitiba and one in Fortaleza, Salvador
and São Paulo. There was also a report of use of injectable pethidine in
Recife and one of injectable morphine in Porto Alegre. However, the
most recent version of this survey, which assesses drug use among street
children and adolescents, does not mention opioid drugs.
The latest and also more comprehensive Brazilian survey is the I
home survey of psychotropic drug use in Brazil, which includes the
107 largest cities in the country (towns with a population of more
than 200,000 people). The sample included 8,589 persons between
12 and 65 years of age who were interviewed. Lifetime use of any
other substance except alcohol and tobacco was reported by 19.4%
of those assessed. Non-medical use of opioids can be deemed relatively
infrequent, lifetime use of codeine-containing syrups was reported by
2.0% of those interviewed, opioid use by 1.4% and heroin by 0.4%.
Lifetime use of codeine-containing syrups is higher among interviewees
aged 35 and over (2.3%) and use of opioids is higher among those
aged 25 to 34. There was a trend towards higher lifetime use among
women (codeine: 2.4%; opiates: 1.6%) than among men (codeine:
1.5%; heroin: 1.1%). The data for heroin are rather limited.8
There have been considerable studies performed in Brazil on
the use of alcohol and drugs among medical students, but none
among doctors.
Opioids – General aspects
Most opioids are important medications employed for specific
medical purposes. Their high dependence-inducing potential,
however, demands care during the administration of these
psychoactive substances.
1. History
There are historical reports on the use of opioids such as those
descriptions of Assyrian ’poppy’ art dating from 4000 BC and
from studies of Egyptian, Greek, and Persian cultures. The term
opium derives from the Greek word for ‘juice’ and refers to juice
from the poppy plant Papaver somniferum.9
In the nineteenth century, millions of Chinese people became
addicted to opium after smoking, eating, drinking, or sniffing it.
Purified derivatives of poppy latex, such as morphine, were
available. Named after Morpheus, the Greek god of dreams,
morphine was isolated from opium in 1806 by Serturner. In rapid
succession, many of 20 distinct alkaloids of opium were isolated,
including codeine in 1832 and papaverine by Merck in 1848,
with many of these alkaloids continuing to be used and abused.
With the availability of parenterally administered opiates and
the invention of the hypodermic syringe, opiate addiction and
opiate withdrawal distress became major worldwide public health
problems. By the twentieth century, opioid addiction was a
widespread problem in the United States.10
In Brazil cases of opioid dependence were reported with remarkable
frequency until the mid-1930s, as shown by the sanatorial statistics
in the largest cities, particularly Rio de Janeiro and São Paulo. In
the state of Rio de Janeiro, for instance, ’fuméries d’opium’ could be
found in small broken-down buildings by the docks. These so-called
’blacksmith’s alleys’ were places where people of different social
classes gathered together to consume the substance.11-12
The post-modern world can be characterized by several changes
in habits and behavior, including a frightening increase in the
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use of drugs throughout the world. This has included an increase
in opioids as drugs of abuse.13
2. Opioids – Classification
The word opioid is assigned to any substance, whether
endogenous or synthetic, that presents, to a varying degree,
morphine-like properties. The term opiate is frequently used to
refer to synthetic opioids.12
Opioids can be classified as natural, semi-synthetic and
synthetic, as is shown in Table 2.
Opioids act in the central nervous system (CNS) and in peripheral
organs, such as  bowels. There are at least four types of specific
receptors for opioids, situated primarily in the sensory, limbic and
hypothalamic areas, amygdala and periacqueductal cineritious, i.e.:
Mu () – subtype 1 accounts for the symptoms of analgesia,
elation and respiratory depression; subtype 2 mediates
gastrointestinal (GI) effects, like constipation;
Kappa () – mediates analgesia, sedation, miosis, dysphoria and
psychotomimetic symptoms as depersonalisation and derealization;
Delta () – mediates analgesia and may be associated with
mood changes;
Epsilon () – may be associated with sedation.14
3. Opioids – Neurobiologic aspects
Despite the use of opium for thousands of years, it was only in
the 1970s that the existence of opioid receptors became a reality
and subsequently endogenous opioids were identified. Although
opioid receptors’ biology is well known, the physiological systems
regulated by opioids and responsible for the analgesic effects and
for other actions are partially known.15
The opioid receptors are coupled to G° and Gi proteins and the
inhibitory actions of opioids occur from the closing of calcium channels
(in the case of kappa receptor) and the opening of potassium channels
(for mu and delta receptors). These actions either result in reduction
in transmitters’ release or depression of neuronal excitability depending
on the pre- or postsynaptic location of the receptors.
Acutely, opiates inhibit Locus coeruleus (LC) via activation of an
inward rectifying K+ channel and inhibition of an inward Na+ flow.
Chronically, LC neurons develop tolerance to these acute inhibitory
actions of opiates, as neuronal activity recovers toward pre-exposure
levels. Abrupt cessation of opiate treatment, for example, causes a
marked increase in neuronal firing rates above pre-exposure levels.16
Located in the dorsolateral pontine tegument of all mammals,
the nucleus LC is the largest grouping of norepinephrine-
containing neurons in the brain. It has been suggested that a
single LC cell probably projects to the brain, hippocampus, and
cerebellum simultaneously, forming a tree of collateral axons.
The LC hyperactivity seen during opioid withdrawal is responsible
for many symptoms of the opioid withdrawal syndrome.17
Increasing evidence indicates that the mesolimbic dopamine
system – consisting of dopaminergic neurons in the ventral
tegmental area (VTA) and their projection regions, most notably
the nucleus accumbens (Nac) – plays an important role in
mediating the reinforcing actions of opiates on brain function.18
Based on the heterogeneous distribution of opioid receptors in
the brain, many neurons and pathways are affected by different
opioid agonists.19
It has been postulated that many opioid receptors are located in
the post-synaptic region. Thus, opioids modulate the release of
neurotransmitters such as acetylcholine, serotonin, epinephrine
and other peptides, like P substance. Some studies, however,
suggest the possibility of different neuromodulations, according to
the type of receptor stimulated. For instance, the activation of Mu
type () receptors in cortical regions of rats induces the inhibition
of norepinephrine release, while the stimulation of Kappa type ()
receptors inhibits striate dopamine release and the activation of
Delta () receptors inhibits acetylcholine release.20-21
4. Opioids – Clinical aspects
Opioids are centrally activating at low dosages and sedating at
higher dosages. They are important and valuable drugs used in
medicine.22 However, a review of the use of opioid medications
for other medical conditions besides addiction, such as pain, is
outside the scope of the present review.
1) Clinical syndromes associated with opioid use
There are three pathological clinical syndromes associated with
opioid use: Intoxication, Abuse and Dependence (or what can
also be referred to as Addiction). In addition, Opioid Withdrawal
is a common clinical syndrome typically associated with the abrupt
cessation or marked decrease in opioid use by a person physically
dependent upon opioids.
a) Opioid intoxication
Opioid intoxication is characterized by analgesia, feelings of euphoria
or dysphoria, feelings of warmth, facial flushing, itchy face, dry mouth,
and pupil constriction. Intravenous use of an opioid can cause lower
abdominal sensations described as an orgasm-like ‘rush’. This is followed
by a feeling of sedation (called the ‘nod’) and dreaming. Severe
intoxication may cause respiratory suppression, areflexia, hypotension,
tachycardia, apnea, cyanosis, and death (Table 1). This clinical picture
may be treated in clinical emergency services.23
The relationship between the symptoms of Opioid Intoxication
and dose of opioid can vary as a function of the person’s level of
physical dependence, history of opioid use, and the acute dose
and route of administration of the opioid ingested.
b) Opioid abuse
According to DSM-IV-TR, Opioid Abuse is a maladaptative pattern
of opioid use leading to clinically significant impairment or distress,
as manifested by one (or more) of the following, occurring within
a 12-month period:
i) Recurrent substance use resulting in a failure to fulfill major
role obligations at work, school, or home);
ii) Recurrent substance use in situations in which it is physically
hazardous;
iii) Recurrent substance-related legal problems;
iv) Continued substance use despite having persistent or
recurrent social or interpersonal problems caused or exacerbated
by effects of the substance.
The symptoms of Opioid Abuse have never met the criteria for
substance dependence for this class of substance (APA, 2000).24
c) Opioid dependence
The opioid dependence syndrome is characterized by a clustering
of signs and symptoms associated with pathologic use of opioids. It is
defined as a maladaptive pattern of substance use, leading to clinically
significant impairment or distress, as manifested by three (or more) of
the following, occurring at any time in the same 12-month period:
i) Tolerance, as defined by either of the following:
1) A need for markedly increased amounts of the substance to
achieve intoxication or desired effect;
2) Markedly diminished effect with continued use of the same
amount of the substance.
ii) Withdrawal syndrome;
i) The substance is often taken in larger amounts or over a
longer period than was intended;
iv) There is a persistent desire or unsuccessful efforts to cut
down or control substance use;
v) A great deal of time is spent in activities necessary to obtain
the substance, use the substance, or recover from its effects;
vi) Important social, occupational, or recreational activities are
given up or reduced because of substance use;
vii) The substance use is continued despite knowledge of having a
persistent or recurrent physical or psychological problem that is likely
to have been caused or exacerbated by the substance (APA, 2000).24
d) Opioid withdrawal
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Table 2 – Signs and Symptoms of opioid intoxication and withdrawal
Intoxication Withdrawal
Activation or “rush” (with low dosages) and sedation/apathy
(with high dosages)
Euphoria or dysphoria
Feelings of warmth, facial flushing, or itching
Impaired judgement, attention or memory
Analgesia
Constipation
Pupillary constriction
Drowsiness
Respiratory depression, areflexia, hypotension,
tachycardia
Apnéia, sedação, coma
Depressed mood and anxiety. Dysphoria
Cravin
Piloerection, lacrimation or rhinorrhea
Frequently, “high” attention
Hyperalgesia, joint and muscle pain
Diarrhea and gastrointestinal cramping, nausea, or vomiting
Pupillary dilatation and photophobia
Insomnia
Autonomic hyperactivity (e. g., hyperreflexia, tachycardia,
hypertension, tachypnea, sweating, hyperthermia)
Yawning
SOURCE: Martin e Hubbard, 200023
Symptoms of opioid withdrawal can include hyperalgesia,
photophobia, goose flesh, diarrhea, tachycardia, increased blood
pressure, gastrointestinal cramps, joint and muscle pain , anxiety
and depressed mood (Table 1).23
2) Absorption and pharmacokinetics of opioids
The pharmacokinetic properties of different opioids vary widely.
Most of them are well absorbed by subcutaneous and intramuscular
routes, while gastrointestinal tract absorption varies among different
opioids. By virtue of the first-pass effect through the liver, some
orally administrated opioids become less potent. Hepatic metabolism
is the primary method of inactivation of these substances, usually
by glicuronide conjugation. Methadone and codeine do not have
a significant first-pass effect, justifying their oral administration.25
Morphine, on the other hand, has a slow and erratic absorption
by the oral route and is generally administered by the intravenous
or intramuscular routes in the management of chronic pain.
Table 3 shows a few opioids, with their corresponding
administration routes and elimination half-lives.
Approaches to the treatment of opioid dependence
The main forms of treatment for substance use disorders are:
psychotherapies, mutual self-help groups (Narcotics
Anonymous), inpatient treatment, outpatient treatment and
psychopharmacological treatment.
Pharmacological treatment is usually restricted to the
management of intoxication, withdrawal syndromes, drug-induced
aggression or behavioral changes, medical complications and,
in some cases, there is a need to use agonist compounds that
bind competitively to the same receptors that mediate the effects
of the abused drugs, preventing or even hindering their effects.26
Unlike other substance addictions, the pharmacological
management of opiate dependence seems to play a crucial role,
whereas other methods of approach display questionable
effectiveness.27-28
1. Management of Opioid Intoxication (including opiod overdose)
The opioid intoxication itself does not lead individuals to seek
medical treatment, except in cases of overdose.
Opiate overdoses usually take place in persons with  low tolerance or
who are relatively inexperienced in opioid use, in addicts that mix opioid
use with other CNS depressant drugs (such as benzodiazepines,
ethanol, or barbiturates) and in persons who err in the  dosage.
The management of cases of opioid overdose, which should
occur in medical emergency units, includes:
a) Establishment of an adequate ventilatory support;
b) Correction of hypotension;
c) Management of pulmonary edema. Remember that the
pulmonary edema is related to leakage in pulmonary capillaries rather
than to fluid overload. Diuretic drugs are therefore contraindicated;
d) Coma and respiratory depression are common findings in these
cases. The use of naloxone is proposed for all cases in which there
is suspicion of opioid overdose. The following schedule is suggested:
i) Administrate 0.8 mg of naloxone IV, waiting for the patient
to wake up. If there is no response in 15 minutes, 1.6 mg of
naloxone IV can be given. If even then there is no response, 3.2
mg of naloxone IV are given and one waits 15 minutes more. If
there is no response, such as mydriasis, agitation, improvement
in the level of consciousness and of the respiratory pattern, it is
imperative to review at once the diagnosis of opiate intoxication;
e) Assessment of body temperature. If feverish, check for
infections, including aspiration pneumonia, endocarditis,
cellulites, meningitis, HIV and hepatitis;
f) Seizures induced by meperidine are reversed by the use of
naloxone29.
2. Pharmacological treatment of the Opioid Dependence
Syndrome
Physical dependence to opioids develops rapidly. Preclinical studies,
and similar work in humans, suggest that adaptational changes
occur with ingestion of the first dose of an opioid (called ‘acute
physical dependence’). Mild or moderate opioid withdrawal symptoms
may be seen after a regular use of an opioid for only a few days.
There are two pharmacological approaches for the treatment
of Opioid Dependence:
a) Supervised withdrawal (also known as detoxification) – This
can vary by both the length of the treatment (for example, relatively
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Table 3 – Opioids: Aspects of pharmacokinetics and dosing via
Drug Dosing route Pharmacokinetic aspects
Half-life 3-4 hours
Converted to active metabolite
(morphine-6-glicuronide)
Half-life < 1 hour
Partly metabolized to morphine
Half-life > 24 hours
No active metabolite
Half-life 2-4 hours
Active metabolite (norpethidine)
Half-life de 12 hours
Slow onset of action
Inactivated by the oral via due to
first-pass effect
Half-life de 1-2 hours
Acts as pro-drug
Metabolized to morphine and other
active opioids
Morphine
Heroin
Methadone
Pethidine
Buprenorphine
Fentanyl
Codeine
Oral (including the slow-release form),
intravenous, intramuscular, intrathecal
Intravenous, intramuscular, smoked, oral
Oral, intravenous, intramuscular
Oral, intramuscular
Sublingual, intrathecal, subcutaneous,
intravenous, intramuscular
Intravenous, epidural, transdermal patch
Oral
SOURCE: Rang et al 200019
brief withdrawals that last up to 30 days or protracted withdrawals
that last for more than 30 days), and by the type of medications
used (substitution therapies versus symptomatic treatments).
b) Maintenance – In general, this form of treatment involves
continuous medication administration without dose tapering (or
withdrawal), and can last for years 30.
1) Supervised withdrawal (or detoxification)
a) Brief versus Protracted withdrawal
In general, evidence suggest that outpatients have a greater
likelihood of success in achieving and maintaining abstinence
from opioid use when supervised withdrawal is conducted over
longer rather than shorter periods. Specifically, clinical experience
suggests that outpatient withdrawals of 4 weeks or less are more
likely to produce relapse to opioid use compared to withdrawals
that last 26 weeks. When withdrawal is conducted on an inpatient
basis, briefer withdrawals are possibly and often successful given
the supervision and support of the inpatient environment.
2) Medications used for supervised withdrawal
a) Substitution therapies
Substitution medications are pharmacotherapies from the same
class of the abused substance. They can be either the same
substance which was abused, or a similar substance. There are
currently two primary substitution medications used for withdrawal
of opioids: methadone and buprenorphine.27
i) Methadone
Methadone is the most commonly used medication for the
treatment of opioid withdrawal.
When dosed orally, onset of effects is gradual and peak plasma
levels occur at 4 hours; 90% of methadone is protein bound.31
Methadone has good oral bioavailability, a long half-life that
allows once daily dosing, and at sufficient doses produces both
suppression of opioid withdrawal symptoms and blockade (or cross-
tolerance) to the effects of other opioids. In addition, it produces
minimal side effects. Methadone is the most widely used
pharmacotherapy for opioid dependence, and should be
considered a first choice in the treatment of opioid withdrawal.32
The treatment of the opioid withdrawal syndrome in the
Interdisciplinary Study Group on Alcohol and Drugs of the Psychiatric
Institute of the Clinical Hospital of the Medical School of the University
of São Paulo (GREA-IPq-HCFMUSP) involves a short-term medically
supervised withdrawal that occurs at an inpatient setting and utili-
zes methadone as the primary pharmacological intervention.
The protocol used is based upon the definition of Withdrawal
Syndrome defined by the following four criteria:
- Mydriasis;
- 10 mm Hg rise in systolic blood pressure;
- 10 beats/minute rise in heart rate;
- the whole set: sweating, chills, sighs, body pain, diarrhea,
rhinorrhea, lacrimation.
If the patient has two or more criteria, he will receive methadone
–10 mg. The patient is checked every 4 hours throughout the
first day in the hospital and a 10 mg dose of methadone is given
in case he presents two of the above criteria. The total methadone
dose in the first 24 hours, which rarely is greater than 50 mg, is
defined as the stabilization dose. In the second day this same
dose is split into two dosages. The total daily methadone dose is
then reduced in increments of 5 mg/day until the completion of
discontinuance. Following the last dose of methadone, clonidine
is given in a dosage of 0.3-1.2 mg, aiming to prevent or relieve
the noradrenergic symptoms due to the Withdrawal Syndrome.12
Our protocol does not begin clonidine until methadone treatment
has been completed. However, some researchers have suggested
that clonidine should be started before the complete
discontinuance of methadone and proposed an introduction
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Table 4 – Equivalence of doses among the opioids
1 mg de methadone corresponds to:
1-2 mg of heroin;
3-4 mg of morphine;
30 mg of codeine;
20 mg of meperidine;
0.5 mg of dilaudid;
7-8 ml of paregoric;
3 ml of laudanum
SOURCE: Kleber, 199426
schedule for clonidine by the time methadone dose reaches 30
mg/day, during the discontinuance phase.33
Methadone may be also used on an outpatient basis for opioid
withdrawal. When used in this manner, doses are typically
reduced on a less than daily basis (often weekly, or at even
greater time intervals), and reductions may occur in progressively
smaller increments as daily doses reach 30 mg or less. Such
methadone withdrawals are usually conducted in methadone
treatment clinics, which are described in more detail later in this
document. In general, patients have better long-term outcomes
with methadone maintenance rather than methadone withdrawal,
even when such withdrawals occur over several months.
The outpatient use of methadone is carried out in many countries
where there is a strict system for the distribution of the medication.
Opioid dependent patients in methadone treatment often come
daily to the treatment centers and obtain the medication directly
from the person in charge of its distribution.34
ii) Other substitution medications
Other substances can be used in the management of the Opioid
Dependence Syndrome. Other opioids, with longer half-life than
that of the drug abused, are often used for the replacement and
progressive tapering of the substance.35 In these cases it is useful to
have available a table correlating the doses of the different opioids,
so as to provide an effective treatment, as shown by Table 4.
In Germany, for example, codeine is the opioid more commonly
used in the management of the Opioid Dependence Syndrome.35
iii) Buprenorphine
Buprenorphine, a partial agonist of mu () type opioid receptors,
has shown promising results in the management of the Opioid
Withdrawal Syndrome.36 Buprenorphine is more potent than
meperidine, can be given by sublingual or parenteral routes, has a
long half-life, and has a relatively low abuse potential (although it
has been misused by injectable route). When used for maintenance
treatment (described in more detail below), the recommended dosage
is 8-16 mg/day. Buprenorphine is equally effective when given thrice
a week, for it has a slow dissociation from opioid receptors.
Several studies have examined the use of injectable buprenorphine
for relatively rapid opioid withdrawal (i.e., withdrawals in less than 2
weeks). In general, injectable buprenorphine is effective – it suppresses
symptoms of withdrawal, and is well tolerated and safe. When compared
to clonidine, buprenorphine appears to produce greater early withdrawal
symptom relief and less adverse effects such as lowered blood pressure.37
In France, buprenorphine was associated with some deaths, whether
due to overdose or to association with other CNS depressants.38
One disadvantage for buprenorphine is that it may not produce
sufficient opioid agonist effects to compensate patients with higher
levels of physical dependence. Studies with buprenorphine have
primarily focused upon its use as a substitution maintenance
medication rather than for withdrawal, and most countries have
focused upon the former indication.
b) Non-substitution therapies: clonidine, symptomatic treatments
Clonidine, an alpha-2 agonist, is effective in the reduction of
opioid withdrawal signs and symptoms such as sweating, piloerection,
tingling, nausea and vomiting. It has minimal or no effect, however,
in reducing opioid craving. The results from treatment of the
Withdrawal Syndrome with clonidine in the literature are
controversial. The reported effectiveness ranges from 0%-30% for
outpatient treatments and 80% -90% for inpatient treatments.9,36
When used for the treatment of opioid withdrawal, clonidine
doses range from 0.6-1.2 mg/day. The two primary side effects
associated with clonidine use for opioid withdrawal are hypotension
and sedation. Clonidine is not recommended for patients with a
recent history of stroke, pregnant women and heart disease patients.
Other symptomatic medications can also be used for treatment
of opioid withdrawal. These can include non-steroidal anti-
inflammatory drugs (NSAIDs) for muscle and joint pain, antiemetics
for nausea and vomiting, and sedatives for sleep disturbance.
2) Maintenance
The maintenance treatment of opioid dependent patients is one
of the most extensively evaluated treatments in the field of addictions.
In general, it is characterized by a period of more than 180 days of
medication use. Several medications are available for this modality
of treatment, such as methadone, buprenorphine, clonidine, LAAM,
other opioids (codeine, tramadol) and at least 15 days after the
withdrawal of any opioid, naltrexone.
It must be pointed out that throughout the treatment, these
patients should be engaged in another therapeutic approach, such
as mutual help groups, psychotherapies or psychosocial support.
Two drugs are prescribed for opioid dependence in France:
methadone and high dosages of buprenorphine. There are no
specific guidelines for choosing between the two products.
a) Methadone
The reasons for choosing methadone are: possibility of oral
administration, long half-life, lesser likelihood of variations in
plasmatic concentration what would  imply in prevention of withdrawal
symptoms, greater compliance by the patients engaged in methadone
programs, significant decrease in non-prescription opioid intake and
legal problems, reduction of ’overdose’ episodes and reduction of
risk behavior for infectious and transmissible diseases.32
Maintenance treatment with methadone is carried out in many centers
in the USA and Europe.30 Those centers employ criteria such as:
i) Patients must be at least 18 years old; if minors, the legal
guardian must authorize and follow up the treatment;
ii) A urinalysis has to confirm opioid use;
iii) Presence of needle marks (in case of injectable drugs);
iv) Presence of withdrawal symptoms. This criterion is not
needed in three circumstances: pregnant women, patients who
are inmates of correctional facilities and patients known to have
previously taken part in such a treatment.27,30
This approach is one of the main models of pharmacological
management used and studied.40-41
Methadone maintenance treatment, however, has several
positive aspects, for it is a safe and effective therapy, it seems to
improve the patients’ nutritional state, reduces antisocial behavior,
enhances professional life, promotes social reinsertion, reduces
risk behavior (intravenous drug use, syringe and needle sharing)
and increases the patient’s compliance with treatment.42-43
Pregnant women should not go through the opioid detoxification
treatment before the 14th gestational week, due to the risk of
induction of abortion, or after the 32nd week, due to the risk of
premature labor.44
Despite the effectiveness of methadone maintenance treatment,
there are critical needs to develop alternatives to methadone for
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opioid agonist maintenance treatment. Problems with methadone
maintenance include its limited availability, the need for daily
dosing, possible diversion of take-home doses, the potential for
opioid overdose for patients who use illicit opioids, and difficult
withdrawal from methadone. The need for daily dosing and
consequent initial requirement for daily clinic attendance may
deter many patients from receiving treatment by this modality.45
b) Buprenorphine
Buprenorphine has a long duration of action, blocks the euphoric
effects of opioids and produces only few withdrawal symptoms following
abrupt cessation of use.46 It could be an alternative to methadone
maintenance pharmacotherapy and may also have a role in helping
patients in their transition from methadone maintenance to treatment
with an antagonist such as naltrexone. It has also been used to
decrease opiate withdrawal symptoms. The opioid-like euphoric effects
of buprenorphine may lead to psychic dependence.47
Buprenorphine is a relatively new drug that, compared with
methadone, seems to be safer in case of overdose, may have an
easier withdrawal phase, and can be used on an alternate day
dosing schedule in most patients. A number of randomized clinical
trials have reported that buprenorphine is as effective as methadone
for the use in maintenance therapy of opioid dependent patients.48
However, many heroin users are initially reluctant to consider
maintenance treatment, but after experiencing the stability
produced by buprenorphine during outpatient detoxification, they
often choose to remain on the drug for prolonged periods.49
Due to its partial agonist properties in mu () receptors, with high
affinity, low intrinsic activity and slow dissociation from the receptors,
this medication implies more therapeutic safety, lesser potential for
physical dependence than other opioids and greater flexibility of dosing.
It is characterized by low oral bioavaliability and high liposolubility.38
This partial agonist of opioid receptors is approved by the U.S. Food
and Drug Administration (FDA) for treatment of opioid dependence.37
The dose of sublingual buprenorphine used in the treatment of
opioid dependence varies, and the maximum dosage has been
as high as 32 mg/day in some clinical trials. Under certain
circumstances, buprenorphine can act as an opioid antagonist
precipitating a withdrawal state.
This medication can be given sublingually either daily or thrice
a week and it has shown very significant results in the
maintenance treatment of opioid dependent patients.37 Laqueille
et al50 reported that the use of buprenorphine is indicated for
patients with less than 10 years’ history of opioid use and no
depressive symptoms associated.
Johnson and McCagh51 pointed out the promising possibility of
the association of buprenorphine with naloxone in the management
of opioid dependent patients. This association was reportedly effective
in keeping patients in treatment, reducing the use of other opioids
and decreasing opioid craving. However, they stated that the use of
this combination may precipitate rather severe withdrawal states.
Pharmacological interactions between any of the consumed
products can be dangerous. Some scientific publications have
reported deaths related to the association of benzodiazepines with
high dosage of buprenorphine.52
c) Clonidine
In spite of its questionable efficacy, this 2 agonist is an alternative
for the maintenance treatment of opioid dependent patients, aiming
to relieve the adrenergic symptoms of the withdrawal syndrome.
The recommended dosage is 0.3-1.2 mg/day.9
d) Levo-alpha-acetylmethadol (LAAM)
LAAM is a synthetic opioid agonist with an action that is
qualitatively similar to morphine, a prototype -agonist that affects
the central nervous system and smooth muscles. The main actions
of LAAM, to which tolerance develops over time, are analgesia
and sedation. An abstinence syndrome, similar to that observed
with other opiates but with slower onset, less intensity, and a
more protracted course, occurs on cessation after chronic dosing.
After oral administration, LAAM is well absorbed in the
gastrointestinal tract. It is metabolised by sequential n-
demethylation to nor-LAAM and dinor-LAAM, with a half-life of
approximately 2 hours for the removal of one N-methyl group.53
The clinical advantages of LAAM are related primarily to its slow
onset and long duration of action. These advantages are both
pharmacological and logistic. Pharmacologically, the slow onset of action
makes LAAM less subject to abuse because addicts tend to seek an
immediate ’pacing out’. The longer duration of action provides a smoother
blood level with less fluctuation between doses. Logistically, less frequent
dosing means less paperwork, less record keeping, and less dose
preparation time, enabling clinics to treat a larger number of patients.
The initial dose depends on the patient’s degree of dependence.
In general, the recommended initial dose for street addicts is between
20 and 40 mg with successive every-other-day dose adjustments of
5-10 mg until a pharmacokinetic and pharmacodynamic steady
state is reached, usually within 1 or 2 weeks.
For patients who are already receiving methadone maintenance
most can transfer to LAAM at a three-per-week dose that is slightly
higher than their daily methadone dose. The recommended dose
of LAAM is 1.2 to 1.3 times the patient’s daily dose of methadone,
not to exceed 120 mg. Subsequent doses, administered at 40 to
72 hour intervals, can be adjusted according to clinical response.
The crossover from methadone to LAAM should be accomplished
in a single dose; complete transfer to LAAM is simpler and
preferable to more complex regimens that involve escalating do-
ses of LAAM and decreasing doses of methadone.
LAAM should never be given daily. Most patients will stabilize
on LAAM doses in the range of 60 – 90 mg three times per
week. Doses as low as 10 mg and as high as 140 mg have been
used successfully in clinical trials.
Adverse reactions to LAAM in opioid-dependent patients are
rare. Side effects are nausea, vomiting, constipation, excessive
sweating, decreased sexual interest, and delayed ejaculation.
LAAM is an opioid agonist with a long duration of action. It is
metabolised into two metabolites with long half-lives, nor-LAAM
(half-life 62 hours) and dinor-LAAM (half-life 162 hours), which
are both more potent than the parent compound (half-life 47 hours).
These long half-lives allow the medication to be given thrice a
week. It must be pointed out that it takes two to three weeks for
LAAM to reach an optimal ’steady state’ and that a rapid dosage
increase carries the risk of overdose, due to cumulative dosing.54
Several recent studies have shown that LAAM is effective for
the treatment of opioid dependence, as reflected by the reduction
of withdrawal symptoms, decrease in the intake of other opioids
and negative urinalysis for the detection of opioid metabolites.55
One meta-analysis carried out by Farré et al56 (2002) showed
that patients treated with LAAM were less compliant to treatment
than those treated with methadone.
LAAM was associated with the development of a rare form of ventricular
tachycardia, known as ‘torsades de pointes’, in which the amplitude of
the ventricular complexes varies within a sinusoidal pattern, with small
amplitude complexes bridging opposite polarity phases.57 It has been
withdrawn off the U.S. and European markets as of 2004.
e) Naltrexone
This opioid antagonist is an effective treatment for addicts with
high motivation to recover and with the social supports that
eventually encourage total abstinence. Naltrexone is taken orally
three times weekly in doses of 50 to 100 mg on weekdays and
100 to 150 mg at weekends. Naltrexone acts as an opiate
antagonist by discriminately binding with opiate receptors and,
thereby, blocking the effects of heroin, methadone, or exogenous
opiates. This medication has been used effectively as an interim
Treatment of patients with opioids dependence syndrome / Baltieri DA et al Rev Bras Psiquiatr. 2004;26(4):259-68
266
phase in opioid addiction and total abstinence in those patients
actively engaged in psychotherapy and Alcoholics Anonymous
and Narcotics Anonymous. A period of 10 to 15 days after last
opiate should elapse before starting naltrexone.37,58
Many opioid-addicted patients have very little motivation to take naltrexone
and to remain abstinent. However, patients with better identified motivation,
among them groups of recovering professionals (physicians, attorneys)
and federal probationers who face loss of license to practice a profession
or legal consequences, have significantly better success with naltrexone.27
f) Other opioids
The use of opioids with longer half-life than the drug abused,
given orally, is an option often used in centers where methadone,
buprenorphine or LAAM are not available.
3. Psychosocial treatments
Psychosocial interventions are a key component of a treatment
plan that includes a strategy to facilitate abstinence from opioids.
The psychotherapeutic approaches to dependence range from
traditional psychoanalysis to cognitive-behavioral techniques.59
Mello et al60 separated didactically the psychotherapeutic
approaches used for the treatment of substance dependence:
1) Psycho-educational – Though not exactly a therapeutic
approach, it has been used in several forms of psychotherapy.
Patients and family members should receive the information
required for the understanding of the concept of disease, its signs
and symptoms, the recovery process and the occurrence of relapses.
2) Cognitive-behavioral – this approach has obtained good results
in the management of dependence. It relies on the assumption that
dependent patients may take advantage of the development of new
methods of establishing relationships, including the identification of
stimuli that may provoke relapses and ways to handle the desire to
take alcohol and other drugs. Relapse Prevention is a cognitive-
behavioral treatment combining the training of behavioral skills and
the techniques of cognitive intervention, aiming to assist patients in
the maintenance of the abstinent behaviour.61
3) Insight-oriented psychotherapy – although discredited for
substance dependent patients, it becomes useful to the patient
when included in multimodal approaches.
The techniques of Relapse Prevention have been widely used
in the management of substance dependence for the last two
decades and were proved to be effective for the patients thus
treated.62-63 Irvin et al,64 in a meta-analysis, concluded that the
techniques of Relapse Prevention are effective, particularly when
applied to alcohol and polydrug dependents, as well as when
combined with pharmacological treatment.
Aspects of treatment in Brazil
In Brazil, there are no available specialized clinics for the
maintenance treatment with methadone. Methadone use is thus
restricted to psychiatric hospital inpatients, patients admitted to
clinics for the treatment of substance dependence and general
hospitals. In outpatient settings, the pharmacological maintenance
treatment of opioid dependent patients is carried out using
buprenorphine, naltrexone and clonidine, according to the
guidance cited above and based on scientific evidence.
As the use of methadone is the main form of treatment for
opioid addicts , the creation of methadone clinics specialized  in
the treatment of  these patients in Brazil is an important initiative
and should be strongly encouraged.
Based on these observations we suggest the below sequential
model for the opiod dependence syndrome treatment:
Figure 1 – Summary of the therapeutic recommendations
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Study performed at the Department on Chemical Dependence of the
Brazilian  Psychiatric Association (ABP).
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